C mplet if Kn wn Substitute for form 1449A/PTO New Application Number INFORMATION DISCLOSURE Herewith Filing Date Randal Eckert First Named Inventor STATEMENT BY APPLICANT TBD Art Unit **TBD Examiner Name** (Use as many sheets as necessary) 2101363-991600 Sheet 1 of 2 Attorney Docket Number

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. § 1.56(a) and 37 C.F.R. § 1.97, Applicant(s) hereby make of record the references listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.

This

disclosure statement.

Info	ormat	ion Disclosure Statement:
(a)	\boxtimes	accompanies a new patent application submitted herewith.
(b)		is filed within three (3) months of the Filing Date or before the mailing date of a First Office Action on the merits; OR
(c)		is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned prior to the mailing date of either a final rejection or a notice of allowance, and is accompanied by either the fee (\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR § 1.97(e), as checked below OR
(d)		is filed after the mailing date of either a final rejection or a notice of allowance, and the issue fee has not been paid, and is accompanied by the requisite petition fee (\$130) set forth in 37

CFR § 1.17(I)(1) and a certification as specified in 37 CFR § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the information

As required under § 1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- Each item of information contained in the Information Disclosure Statement was first cited in (e) a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a (f) communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

It is respectfully requested that each of the references shown on the attached FORM PTO-A820 be made of record in this application. The cited references were previously disclosed in parent Application No. 10/077,624, filed February 14, 2002, and are not enclosed.

Complet if Kn wn Substitute for form 1449A/PTO New **Application Number** INFORMATION DISCLOSURE Filing Date Herewith First Named Inventor Randal Eckert STATEMENT BY APPLICANT Art Unit TBD **Examiner Name TBD** (Use as many sheets as necessary) of 2101363-991600 Sheet 2 Attorney Docket Number

Each item of information listed in the attached FORM PTO-A820, may be material to the examination of the aboveidentified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this submission as a conditional petition for acceptance of the information disclosure statement.

The Commissioner is author	orized to charg	e any deficiencies and	I credit any over	payment of fees
to our Deposit Account No.	07-1896			

Date:

Respectfully submitted,

GRAY CARY/WARE & FREIDENRICH LI

By:

Reg. No. 43,360

Attorneys for Applicant(s)

153 Townsend Street, Suite 800 San Francisco, CA 94107-1907

Tel. 415-836-2500

Fax. 415-836-2501

Customer Number or Bar Code Label

29585

(Insert Customer No. or Attach bar code label here)

Complete if Known Substitute for form 1449A/PTO New Application Number INFORMATION DISCLOSURE Herewith Filing Date Randal Eckert First Named Inventor STATEMENT BY APPLICANT TBD Art Unit TBD **Examiner Name** (Use as many sheets as necessary) Attorney Docket Number 2101363-991600 Sheet 2

Each item of information listed in the attached FORM PTO-A820, may be material to the examination of the aboveidentified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this submission as a conditional petition for acceptance of the information disclosure statement.

The Commissioner is author	orized to charge	any deficiencies and	credit any over	payment of fees
to our Deposit Account No.	07-1896			

Date:

te: 11/12/03

Respectfully submitted,

GRAY CARY/WARE & FREIDENRICH LLP

BA:

Reg. No. 43,360 Attorneys for Applicant(s)

153 Townsend Street, Suite 800

San Francisco, CA 94107-1907

Tel. 415-836-2500 Fax. 415-836-2501

🔀 Customer Number or Bar Code Label

29585

(Insert Customer No. or Attach bar code label here)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)	Application Number		
2101363-991600	New		
Applicant(s)			
Randal Eckert, et al.			
Filing Date	Group Art Unit		
Howannith	TRN		

-									
		,			U.S. PATENT DOCUMENTS	5 	· · ·	 	
*EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5,0	57,313	10-15-91	Lisa B. Shih, et al.	424	1.53	08-23-88	3
	AB	5,7	26,293	03-10-98	Brian Seed	530	413	05-27-94	1
	AC	4,6	71,958	06-09-87	John D. Rodwell	424	1.53	03-09-82	2
	AD	5,9	10,573	06-08-99	Andreas Pluckthun, et a	al. 530	387.3	07-22-94	1
	AE	5,64	46,119	07-08-97	Frank G. Oppenheim, e	t al. 514	12	07-07-95	5
	AF	5,8	51,527	12-22-98	Hans Hansen	424	178.1	05-19-95	5
	AG	5,64	45,835	07-08-97	Henry Fell, Jr., et al.	424	134.1	05-23-94	ļ
	АН	6,19	97,299	03-06-01	Mikael Dohlsten, et al.	424	183.1	09-16-98	3
	ΑI	5,6	72,351	09-30-97	Michael Chikindas, et a	1. 424	401	12-11-95	5
	AJ	6,183,744		02-06-01	David M. Goldenberg	424	141.1	03-12-98	
	AK	5,981,726		11-09-99	Ira Pastan	536	23.53	10-28-94	
	<u> </u>	•			FOREIGN PATENT DOCUM	MENTS	-		
	REF		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Trans	lation NO
	AL	WO 99/58141		11-18-99	Europe	A61K	38/16	~	
	AM	WO 02/22686 A2		03-21-02	Europe	C07K	16/00	>	
				<u> </u>					
			Databasa DIALOC No	BC105051081	•	ncluding Author, Title, D	•	•	cal
Database DIALOG No. BG195051081. NICOLAS, P., "Peptides as Weapons Against Microogranisms in the Cher Defense System of Vertebrates." Annual Review of Microbiology, Vol. 49, pp. 277-304 (1995).						and Cheilli	~~		
		AN							
			International Search R	eport mailed Jar	uary 2, 2003				
		AO							
XAMINE	· P	•			DATE CONSIDER	RED		·-	

Form PTO-A820 (also form PTO-1449)

not considered. Include copy of this form with next communication to applicant.

P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

not considered. Include copy of this form with next communication to applicant.

Docket Number (Optional)	Application Number		
2101363-991600	New		
Applicant(s)			
Randal Eckert, et al.			
Filing Date	Group Art Unit		
Ugrowith	TRN		

		Helevitii 120					
*EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
an HAL	SUE M. TRAVIS, et al., Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides, Infection and Immunity, Vol. 68 No. 5:2748-2755, American Society for Microbiology, May 2000 (United States).						
	AQ	JENS-M. SCHRODER, Commentary: Epithelial Peptide Anti-Biotics, Biochemical Pharmacology, Vol. 57, pp. 121-134,1999, Elsevier Science.					
	AR	MANUEL L. PENICHET et al., Antibody-Cytokine Fusion Proteins For the Therapy Of Cancer, Journal of Immunological Methods, Vol. 248:91-1001 (2000), Elsevier Science B.V.					
	AS	PENG LI et al., An Antimicrobial Peptide Gene Found in the Male Reproductive System Of Rats, Science Vol. 291:1783-1785.					
	АТ	SHERIE L. MORRISON et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains, Proceedings Of The National Academy Of Sciences U.SA. Vol. 81:6851-6855 (1984).					
	AU	STEVEN A. MARSHALL et al., Spectrum and Antimicrobial Activity of Alexomycian: (PNU-82, 127), A Peptide Compound Projected for Use in Animal Health, Diagnostic Microbiology, Infectious Diseases Vol. 33: 181-186 (1999), Elsevier Science, Inc. U.S.A.					
	AV	KENNETH T. MIYASAKI et al., "S-Sheet Anithiotic Peptides As Potential Dental Therapeutics, International Journal Of Antimicrobial Agents, Vol. 9:269-280 (1988), Elsevier Science, B.V.					
	AW	EVA J. HELMEHORST et al., Biochemical Journal, Vol. 326:39-45 (1997), Great Britain					
	AX	ANDREA GIACOMETTI et al., "Antimicrobial Activity Of Polycationic Peptides," Vol. 20:1265-1273 (1999), Elsevier Science, Inc.					
	AY	KATE FORTNEY et al., Haemophilus ducreyi Is Susceptible to Protegrin, Antimicrobia Agents and Chemotherapy, Vol. 42:2690-2693 (1998).					
EXAMINER	1	DATE CONSIDERED					
*EXAMINER: I	nitial if	citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and					

P09B/REV04